Orbis Medicines raised EUR 90 million in a Series A funding round led by NEA to develop their pipeline of next-generation oral macrocycle drugs.
Orbis Medicines raised EUR 90 million in a Series A funding round led by NEA to develop their pipeline of next-generation oral macrocycle drugs.
01/06/25, 11:47 AM
Location
copenhagenMoney raised
€90 million
Industry
biotechnology
Round Type
series a
Investors
Forbion, Novo Holdings, Export And Investment Fund Of Denmark, Cormorant, Eli Lilly And Company, Nea
Orbis Medicines announced the close of a EUR 90 million Series A funding round, bringing their total raised to EUR 116 million. The funds will support the development of their oral macrocycle drugs, called ‘nCycles’, which aim to provide high-value alternatives to traditional biologic drugs.
Company Info
Location
copenhagen, capital region of denmark, denmark
Additional Info
Orbis Medicines is a biotechnology company focused on pioneering a new era for oral macrocycle drug discovery. Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties, defined by the presence of a cyclic structure. Orbis’ nGen platform is designed to systematically explore the macrocycle chemical space using a highly automated chemistry platform and deliver oral macrocycle drug candidates – nCycles – suitable for both intra- and extracellular targets. Orbis’ programs are focused on high-value oral alternatives to blockbuster biologic drugs and targets challenging for established modalities.